A direct communication to health care professionals says that the initial symptoms of anaphylaxis with glatiramer acetate might overlap with those of post-injection reactions and could lead to a delay in identifying an anaphylactic reaction.
Teva and EU medicines regulators have begun notifying health care professionals that cases of anaphylactic reactions to the multiple sclerosis drug, glatiramer acetate, have been reported in some patients immediately after administration but sometimes months or even years after they began their treatment.
Some of the cases of anaphylaxis have been fatal, according to a Direct Healthcare Professional Communication (DHPC) drawn up by...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
